Formulation and evaluation of less-painful clarithromycin lipid microspheres

Archives of Pharmacal Research

Volumn 30, Issue 10, 2007, Pages 1336-1343

  Qin, LingHao ^a   Leng, Wei ^b  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Animal test; Clarithromycin; Entrapment efficiency; Intravenous use; Irritation; Lipid microsphere (LM)

Indexed keywords

ANTIINFECTIVE AGENT; CLARITHROMYCIN; DRUG CARRIER; LIPID; MICROSPHERE;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG FORMULATION; DRUG STABILITY; ERYTHEMA; INTRAVENOUS DRUG ADMINISTRATION; PAIN; PAIN ASSESSMENT; PARTICLE SIZE; PATHOLOGY; RABBIT; RAT; SURFACE PROPERTY; TOXICITY TESTING; WISTAR RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CLARITHROMYCIN; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; ERYTHEMA; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LIPIDS; MICROSPHERES; PAIN; PAIN MEASUREMENT; PARTICLE SIZE; RABBITS; RATS; RATS, WISTAR; SKIN IRRITANCY TESTS; SURFACE PROPERTIES;

EID: 35649025845     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02980275     Document Type: Article

References (30)

1. Akkar, A. and Muller R. H., Formulation of intravenous Carbamazepine emulsions by SolEmuls technology, Eur. J. Pharm. Bbpharm., 55, 305-312 (2003a).
2. Akkar A. and Muller R.H., Intravenous itraconazole emulsions produced by SolEmuls technology, Eur. J. Pharm. Biopharm., 56, 29-36 (2003b).
3. Bates T. R. and Sequeria J. A., Bioavailability of micronized griseofulvin from corn oil-in-water emulsion, aqueous suspension, and commercial tablet dosage forms in humans, J. Pharm. Sci., 64, 793-797 (1975).
4. Burman W. J., Stone B. L., Rietmeijer C A., Maslow J., Cohn D. L., and Reves R. R., Long-term outcomes of treatment of Mycobacterium avium complex bacteremia using a clarithromycin-containing regimen, AIDS.,12,1309-1315 (1998).
5. Caillot, D., Casasnovas, O., Solary, E., Chavanet, P., Bonnotte, B., Reny, G., Entezam, F., Lopez, J., Bonnin, A., and Guy, H., Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients, J. Antimicrob. Chemother., 31, 161-169 (1993).
6. Cannon, J. B., Williams, N. A., and Papp, K. J., Reduction of pain on intravenous infusion with bile salt formulations for a macrolide antibiotic. Int. J. Pharm., 114, 65-74 (1995)
7. Chaisson, R. E., Keiser, P., Pierce, M., Fessel, W. J., Ruskin, J., Lahart, C., Benson, C. A., Meek, K., Siepman, N., and Craft, J. C., Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection, AIDS., 11, 311-317(1997).
8. Cox, E. H., Knibbe, C. A., Koster, V. S., Langemeijer, M. W., Tukker, E. E., Lange, R., Kuks, P. F., Langemeijer H. J., and Lie-Ahuen, L., M. Danhof, Influence of different fat emulsion based intravenous formulation on the pharmacokinetics and pharmacodynamics of propfol, Pharm. Res., 15, 442-448 (1998).
9. Dorota, W. S. and Malgorzata, S., Partitioning of parabéns between phases of submicron emulsions stabilized with egg lecithin, Int. J. Pharm., 312, 174-178 (2006).
10. Engels, T., Forster, T., and Rybinski, W. von, The influence of coemulsifier type on the stability of oil-in-water emulsions, Colloid. Surface. A., 99, 141-149 (1995).
11. Hewitt, R. G., Papandonatos, G. D., Shelton, M. J., Hsiao, C. B., Harmon, B. J., Kaczmarek, S. R., and Amsterdam, D., Prevention of disseminated Mycobacterium avium complex infection with reduced dose clarithromycin in patients with advanced HIV disease, AIDS, 13, 1367-1372 (1999).
12. Jumaa, M. and Muller, B. W., The effect of oil components and homogenization conditions on the physicochemical properties and stability of parenteral fat emulsion. Int. J. Pharm., 163, 81-89 (1998).
13. Jumaa, M. and Muller, B. W., Parenteral emulsions stabilized with a mixture of phospholipids and PEG-660-12-hydroxystearate: evaluation of accelerated and long-term stability. Eur. J. Pharm. Biopharm., 54,207-212 (2002).
14. Kajita, M., Morishita, M., Takayama, K., Chiba, Y., Tokiwa, S., and Nagai, T., Enhanged enteral bioavailability of vancomycin using water-in-oil-in-water multiple emulsion incorporating highly purified unsaturated fatty acid, J. Pharm. Sci, 89, 1243-1252 (2000).
15. Klement, W. J., and Arndt, J. O., Pian on injection of propofol eddects of concentration and diluent. Br. J. Anaesth., 67, 281-284 (1991).
16. Kobayashi, L, Makajima, M., and Mukataka, S., Preparation characteristics of oil-in-water emulsions using differently charged surfactants in straight-through mSrochannel emulsificatSn. Colloid. Surface. A., 229, 33-41 (2003).
17. Kohno Y. Yoshida H., Suwa T, and Suga T, Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide anti biotic and erythromycin in rats, Antimicrob. Agents. Chemother, 33, 751-756 (1989).
18. Langtry, H. D. and Brogden, R. N., Clarithromycin a review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients, Drugs, 53, 973-1004 (1997).
19. Menashe, Y. L., Lev, L., Shoshanna, G. S., and Benita, S., Side-effect evaluation of a new diazepam formulation: venous sequela reduction following intravenous (iv) injection of a diazepam emulsion in rabbits, Pharm. Res., 6, 510-516 (1989).
20. Moore, R. D. and Chaisson, R. E., Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS, AIDS., 9, 1337-1342 (1995).
21. Müller, R. H., Schmidt, S., Buttle, I., Akkar, A., Schmitt, J., and Bramer, S., SolEmuls®-novel technology for the formulation of i.v. emulsions with poorly soluble drugs, Int. J. Pharm., 269, 293-302 (2004).
22. Nakagawa, Y, Ital, S., Yoshida, T., and Nagai, T., Physicochemical properties and stability In the acidic solution of a new macrolide antibiotic, clarithromycin, in comparion with erythromycin, Chem. Pharm. Bull., 40, 725-728 (1992).
23. Onyeji, C. O., Nightingale, C H., Nicolau, D. P., and Quintiliani, R., Efficacies of liposome- encapsulated clarithromycin and ofloxacin against Mycobaterium avium-M. intracellulare complex in human macrophages. Antimicrob. Agents. Chemother, 38,523-527(1994).
24. Peter, D. H. and Clissold, S. P. Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential, Drugs, 44, 117-164 (1992).
25. Pierce, M., Crampton, S., Henry, D., Heifets, L., La Marca, A., Montecalvo, M., Wormser, G. P. Jablonowski, H., Jemsek, J., Cynamon, M., Yangco, B. G, Notario, G, and Craft, J. C., A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N. Engl. J. Med., 335, 384-391 (1996).
26. Salem, I. I. and Duzgunes, N., Efficacies of cyclodextrin-compexed and liposome- encapsulated clarithromycin against Mycobaterium avium complex infection in human macrophages, Int. J. Pharm., 250,403414 (2003).
27. Stampft, D. A. and Franson, T R., Central-vein phlebitis associated with peripheral intravenous administration of erythromycin. Clin. Pharmacol., 5, 604-606 (1986).
28. Takino, T., Konishi, K., Takakura, Y., and Hashida, M., Long circulating emulsion carrier systems for highly lipophilic drugs, Biol. Pharm. Bull., 17, 121-125 (1994).
29. Zimmerm Celis, G. de, Gea, E., Roig, J., Latorre, X., MartínezBenazet, J., and Gómez, J., Comparative Tolerability of Intravenous Erythromycin and Clarithromycin in Hospitalised Patients with Community-Acquired Pneumonia Results of a Double-Blind, Randomised, Prospective Study, Clin. Drug. Invest, 22, 393-398 (2002).
30. Zimmermann, T., Laufen, H., Riedel, K. D., Treadway, G., and Wildfeuer, A., Comparative Tolerability of Intravenous Azithromycin, Clarithromycin and Erythromycin in Healthy Volunteers Results of a Double-Blind, Double-Dummy, FourWay Crossover Study, Clin. Drug. Invest., 21, 527-536 (2001).